Older woman getting a tutorial on how to use her medicine from a medical professional

Prescription drug monitoring

Ensure optimal patient treatment with our clinical drug testing portfolio. Tailored to manage medication compliance and identify risky drug interactions, our ToxAssure Flex prescription drug monitoring tests offer unparalleled choice and clinical value, supporting your patients effectively

View the ToxAssure® Flex Portfolio(Opens in a new window)
supporting image

Simplifying clinical toxicology choices

Clinical toxicology is a complex science, and we know that choosing the right drug test can be challenging.

Labcorp’s ToxAssure Flex portfolio provides flexible options for answers you can trust, including:

  • Test options for over 200 drug compounds

  • Presumptive, presumptive with reflex to definitive, and definitive testing (when possible)

  • Choice of individual drug classes by mixed methodologies as single tests, or along with others as part of a panel

  • Confirmatory drug class testing and analysis for those performing in-house drug screening

  • Blood and oral fluid test options for patients who are unable to provide urine samples

  • Consolidated reports with results and methodology-specific considerations

ToxAssure Flex

Innovative Mixed Methodology Panels: Assay-Driven Solution

Whether you are monitoring a patient’s use of prescribed medications, non-prescribed medications or illicit drugs, our comprehensive test menu allows you to identify several unique metabolites within each drug class, providing flexibility and clinical value in prescription drug monitoring for you and your patients.

ToxAssure Flex Portfolio (Opens in a new window)

Comprehensive support: Labcorp's ToxAssure Flex portfolio 
 

Enhanced specimen validity testing

In addition to standard validity testing of creatinine, pH and specific gravity, a robust series of normal human urinary biomarkers are monitored to distinguish human urine from synthetic urine products.

ToxAssure Flex profile report

Our cumulative reports, available for ToxAssure Flex profiles and individual drug confirmations, track unexpected results based on reported medications and illicit drugs. Easily monitor and improve trends with our convenient report format, facilitating review of patient results and medication use over time.

Support hotlines

With direct, toll-free access to certifying scientists, you can engage in one-on-one consultations about test results and toxicology questions.

For test menu inquiries, add-on or test change requests, results status and interpretation and technical discussion of patient-specific drug test results

Definitive drug testing

Definitive testing for confirmatory drug screening

Are you performing in-office drug screening? Labcorp’s ToxAssure Flex portfolio includes direct order confirmation tests for unequivocal determination of drug identification and quantitation.1 Our confirmation tests can be ordered individually to confirm targeted drugs (e.g., specific drug results from in-office screening). 

Explore Drug Class Testing Options (Opens in a new window) Utilize the Definitive Testing Resource (Opens in a new window)

Additional Resources
 

FAQs

 

  • Labcorp’s ToxAssure, ToxAssure Flex, and MAT testing results are normalized to the creatinine concentration in that urine sample. This approach allows for addressing the variability in drug concentrations due to the hydration status of the patient at the time of collection.  

  • Immunoassay screening tests detect the presence of a class of drugs compared with confirmatory testing performed by gas chromatography/mass spectrometry (GC/MS) or liquid chromatography/tandem mass spectrometry (LC/MS-MS) for unequivocal determination of drug identification and quantification.  

    There are several factors such as screening thresholds and drug cross-reactivity which may account for discordance between immunoassay and confirmation testing results.  You can reference our definitive testing resource (L14987-0123-3) or contact our clinical drug testing support team (877-474-5767/[email protected]) for additional information. 
     

  • See our drug detection range reference here (L686961-1023-1). 

  • Yes, MDMA is included in our amphetamines drug class.

  • Our specimen validity testing identified this specimen as lacking normal urinary biomarkers or containing compounds found in synthetic urine that are not present in normal human urine.  

 

References 

  1. NCCLS. Gas Chromatography/Mass Spectrometry (GC/MS) Confirmation of Drugs; Approved Guideline. NCCLS document C43-A (ISBN 1-56238-475-9). 2002:(22)22. 
  2. Substance Abuse and Mental Health Services Administration. Technical Assistance Publication Series TAP 32: Clinical Drug Testing in Primary Care. SAMHSA.gov. Accessed January 29, 2024. https://store.samhsa.gov/sites/default/files/sma12-4668.pdf